Currently, more than 6 million children in the United States, or 11% of all children aged 4 to 17, have received attention-deficit hyperactivity disorder (ADHD) diagnoses. The disorder is characterized … Continue Reading Neuroimaging shows interactions in attention-based brain networks weaker in children with ADHD.
It is known that the neurons of the human brain communicate with each other through specialized structures called synapses. A synapse consists of a presynaptic terminal of one neuron … Continue Reading Previously unknown molecule critical to synaptic transmission identified.
Hyperactivity and social abnormalities are defining characteristics of ADHD and autism, two developmental disorders that parents and scientists around the world are struggling to understand. At the RIKEN Brain Science … Continue Reading Researchers identify protein responsible for regulating dopamine levels in the brain.
A small neuroimaging study suggests prenatal exposure to polycyclic aromatic hydrocarbons (PAHs), the toxic air pollution caused in part by vehicle emissions, coal burning and smoking, may be bad for … Continue Reading Neuroimaging study links prenatal air pollution exposure to impaired neurodevelopment.
Gene variants implicated in ADHD identify attention and language deficits in the general population.
A new study from researchers at Cardiff University and the University of Bristol suggests that there is a spectrum of attention, hyperactivity/impulsiveness and language function in society, with varying degrees … Continue Reading Gene variants implicated in ADHD identify attention and language deficits in the general population.
A neuroimaging study involving 750 children and teens reveals a key difference in brain architecture between those with attention deficit hyperactivity disorder and those without. Children with ADHD, a new … Continue Reading Neuroimaging study finds slower development of connections in children with ADHD.
Review of ADHD drug approvals highlights gaps between approval process, long-term safety assessment.
Review of ADHD drug approvals highlights gaps between approval process, long-term safety assessment. Over the last 60 years, the U.S. Food and Drug Administration (FDA) approved 20 medications for attention deficit/hyperactivity disorder (ADHD) based on clinical trials that were not designed to study their long-term efficacy and safety or to detect rare adverse events. The study highlights gaps in how the long-term safety of drugs intended for chronic use in children is assessed as part of the FDA approval process.
Thoughts health innovators?
The mental health patient is the forgotten patient…Let’s talk mental illness, does it make you feel uncomfortable? Does it worry you that speaking about it may lead people to believe … Continue Reading Health Innovations in Psychology Part One